The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
CCT3833是一种打破悖论的泛RAF和SRC家族激酶抑制剂,对KRAS突变驱动的癌症有效。
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2020.10.483
Saturno, G; Lopes, F; Niculescu-Duvaz, I; Niculescu-Duvaz, D; Zambon, A; Davies, L; Johnson, L; Preece, N; Lee, R; Viros, A; Holovanchuk, D; Pedersen, M; McLeary, R; Lorigan, P; Dhomen, N; Fisher, C; Banerji, U; Dean, E; Krebs, M G; Gore, M; Larkin, J; Marais, R; Springer, C